8-K: Ontrak Secures $8.45 Million in Convertible Note Financing from Acuitas Capital Amidst Significant Dilution

Ontrak, Inc. has entered into a Seventh Amendment to its Master Note Purchase Agreement with Acuitas Capital LLC, securing a commitment for up to $8.45 million in senior secured convertible promissory notes and potentially more, while also adjusting terms for existing warrants, leading to substantial shareholder dilution.

Summary

• Ontrak, Inc. (the Company) entered into a Seventh Amendment to its Master Note Purchase Agreement with Acuitas Capital LLC (Acuitas) on June 27, 2025, terminating previous agreements and establishing new financing terms.
• Acuitas committed to purchase up to $8.45 million in principal amount of senior secured convertible promissory notes (Committed Demand Notes) and may purchase additional uncommitted notes (Uncommitted Demand Notes).
• The Company can request up to $1.5 million in notes within any 30-day period, subject to conditions including a certification of insufficient unrestricted cash for a 30-day period without the funds and no material adverse change since June 27, 2025.
• The conversion price for the Seventh Amendment Demand Notes is the lesser of $0.9726 and the greater of the common stock's closing price on the trading day prior to conversion or $0.3242.
• Acuitas agreed not to demand payment on any Demand Notes or Seventh Amendment Demand Notes until the earlier of September 1, 2026, or 30 days after Acuitas has purchased the full $8.45 million in Committed Demand Notes.
• The Company will issue warrants to Acuitas with 200% coverage in connection with each Seventh Amendment Demand Note, with an initial exercise price equal to the common stock's closing price on the funding date.
• The conversion price of certain existing Demand Notes issued on March 28, 2025, May 9, 2025, and May 27, 2025, will be amended to be the lesser of their respective closing prices on issuance dates ($1.48, $1.64, $1.59) and the greater of the common stock's closing price prior to conversion or one-third of the respective issuance date closing price, effective upon stockholder approval.
• Acuitas waived its right to require net proceeds from equity financing to be applied to pay down the notes before they are due.
• Acuitas has a 'Committed Seventh Amendment Demand Notes Offset Right,' allowing it to reduce its commitment dollar-for-dollar if the Company receives proceeds from other equity financing.
• The Company is required to seek stockholder approval for the issuance of the Seventh Amendment Demand Notes, associated warrants, and the amendment to existing notes, in accordance with Nasdaq listing rules.
• On June 20, 2025, Humanitario Capital, LLC, an affiliate of Acuitas, exercised 500,000 pre-funded warrants at $0.0001 per share.
• Immediately following this exercise, Acuitas owned 52% of the Company's common stock and beneficially owned 98% of the Company's common stock.
• Holders of Public Offering Warrants and Acuitas Warrants agreed to new exercise price adjustment terms, which include reductions based on the Seventh Amendment and a potential future public offering, potentially leading to further dilution.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the highly dilutive nature of the financing, the company's deep reliance on a single investor (Acuitas Capital), and the aggressive terms of the convertible notes and warrants. While securing funding is positive for liquidity, the cost to existing shareholders in terms of dilution is substantial, and the terms suggest a company in a challenging financial position.

Positives

• Secured a commitment for $8.45 million in additional financing from Acuitas Capital, providing crucial liquidity.
• Acuitas Capital, a major shareholder, has committed to providing ongoing financial support, indicating confidence from a key investor.
• The earliest repayment date for the notes is deferred until September 1, 2026, or 30 days after the full $8.45 million is purchased, providing a clear runway for the company.
• Acuitas waived its right to require net equity proceeds to be used for note repayment, allowing the company to utilize future capital raises for operational needs.

Negatives

• The financing structure is highly dilutive, involving convertible notes and 200% warrant coverage, which will significantly increase the number of outstanding shares upon conversion and exercise.
• The conversion price of the new notes and the exercise price of warrants are subject to downward adjustments based on the company's stock price, exacerbating dilution if the stock price declines.
• The company's ability to draw on the committed funds is subject to a 'no material adverse change' condition, which could be a barrier to funding if the company's performance deteriorates.
• The company is heavily reliant on a single investor, Acuitas Capital, for its financing needs, which concentrates financial risk.
• Existing warrant holders (Public Offering Warrants and Acuitas Warrants) agreed to further reductions in their exercise prices, indicating potential for additional dilution for these investors.
• The beneficial ownership of Acuitas Capital and its affiliate Humanitario Capital LLC reached 98% after recent warrant exercise, indicating near-complete control by a single entity.

Risks

• Significant dilution of existing common stockholders due to the issuance and conversion of senior secured convertible promissory notes and the exercise of associated warrants.
• The Company's ability to access committed funds is contingent on the absence of a 'material adverse change' in its operations, business, or financial condition.
• Failure to obtain stockholder approval for the financing terms could prevent the issuance of shares upon conversion of notes and exercise of warrants, potentially impacting the company's ability to meet its obligations.
• The conversion price of the notes and exercise price of warrants are subject to adjustments based on the company's stock price, which could lead to further dilution if the stock price declines.
• The company's reliance on a single investor (Acuitas Capital) for substantial financing creates a concentration risk.

Future Outlook

The Company intends to seek stockholder approval for the financing terms, potentially by obtaining written consent from Acuitas Capital, which holds a majority of outstanding common stock. If written consent is not feasible, the Company will hold stockholder meetings. The Company also has a Registration Statement on Form S-1 filed for a potential public offering.

Management Comments

• The Company did not deem the exercise of pre-funded warrants by Humanitario Capital, LLC, resulting in Acuitas owning 52% and beneficially owning 98% of common stock, to be a change of control given the control Acuitas and Humanitario already had by virtue of their beneficial ownership prior to such exercise.

Industry Context

This financing arrangement highlights the ongoing capital needs of Ontrak, Inc., a company operating in the healthcare technology or behavioral health sector. The highly dilutive terms and reliance on a single, controlling investor (Acuitas Capital) suggest that the company may be facing significant financial challenges or has limited access to traditional capital markets. Such financing structures are often seen in companies requiring substantial capital infusions to sustain operations or fund growth initiatives, particularly when conventional debt or less dilutive equity options are unavailable or undesirable.

Comparison to Industry Standards

• The 200% warrant coverage and floating conversion prices tied to market performance are significantly more dilutive than typical financing terms for healthy, growing companies, often seen in distressed or high-risk situations.
• The concentration of ownership and financing reliance on a single entity (Acuitas Capital, with 98% beneficial ownership) is atypical for publicly traded companies and can raise corporate governance concerns regarding minority shareholder interests, unlike more diversified investor bases in comparable healthcare tech firms.
• The requirement for stockholder approval for financing terms, despite majority control by the investor, indicates adherence to Nasdaq listing rules, which is a standard governance practice, but the terms themselves are aggressive compared to non-distressed financing.

Corporate Governance

Related Party Transactions

• The Seventh Amendment to the Master Note Purchase Agreement is with Acuitas Capital LLC, which, along with its affiliate Humanitario Capital LLC, owned 52% and beneficially owned 98% of Ontrak's common stock immediately following a recent warrant exercise. This makes Acuitas a controlling shareholder and the financing a significant related-party transaction.
• Agreements with holders of Public Offering Warrants and Acuitas Warrants (including Acuitas Capital LLC and Humanitario Capital LLC) to adjust exercise prices are also related-party transactions, given their existing investment and Acuitas's controlling stake.

Stakeholder Impact

• **Shareholders**: Existing shareholders face significant dilution due to the issuance of convertible notes and warrants, especially given the 200% warrant coverage and floating conversion prices. The substantial increase in Acuitas's beneficial ownership to 98% further concentrates control.
• **Creditors**: Acuitas Capital LLC becomes a secured creditor with a commitment to provide additional financing, and its waiver of early repayment and equity proceeds application provides some stability for the company's liquidity.
• **Employees, Customers, Suppliers**: Indirectly impacted by the company's continued operations and financial stability, which is supported by this financing. No direct impact on these groups is mentioned.

Next Steps

• The Company may request Acuitas to purchase Committed Demand Notes, up to $1.5 million per 30-day period.
• The Company will seek stockholder approval for the Seventh Amendment Demand Notes, associated warrants, and the amendment to certain existing Demand Notes.
• The Company intends to file a preliminary information statement related to stockholder approval and mail a definitive statement.
• If written consent for stockholder approval is not feasible, the Company will hold an annual or special meeting of stockholders for approval, with subsequent meetings semi-annually if approval is not obtained.
• The Company will issue Demand Warrants to Acuitas promptly after the Stockholder Approval Effective Date for notes issued after the initial $15.0 million aggregate principal amount.
• The Company may proceed with an offering under its Registration Statement on Form S-1.

Key Dates

Recommendation

Keywords

Convertible Notes, Warrants, Dilution, Acuitas Capital, Financing, SEC Filing, 8-K, Stockholder Approval, Senior Secured Notes, Capital Raise, Corporate Governance, OTRK